Related Experiment Videos
A double blind placebo controlled trial of ascorbic acid in obesity
Nutrition and Health
|January 1, 1985
Abstract:
A double blind placebo controlled trial of ascorbic acid was carried out in 41 severely obese subjects. 38 patients completed the 6 week trial. 19 received 3g of ascorbic acid per day, 19 received placebo. The weight loss during the trial was small in both groups but was significantly greater in the ascorbic acid treated group.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Does primary Streptococcus viridans pneumonia exist?
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·1992
Acyl-CoA:cholesterol O-acyl transferase (ACAT) inhibitors. 1. 2-(Alkylthio)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.
Journal of medicinal chemistry·1992
Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite.
Archives of biochemistry and biophysics·1992
Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
Screening for alpha-thalassemia. Correlation of hemoglobin H inclusion bodies with DNA-determined genotype.
Archives of pathology & laboratory medicine·1992
Parent gender, victim gender, and family socioeconomic level influences on the potential reporting by nurses of physical child abuse.
Issues in comprehensive pediatric nursing·1992
Association between smoking dependence and intuitive eating in adults in primary care.
Nutrition and health·2026
Are dietary plant cell wall polysaccharides key components to prevent/avert breast cancer?
Nutrition and health·2026
Treatment Initiation of Definitive Radiotherapy in Patients With Locally Advanced Head and Neck Cancer.
Cancer control : journal of the Moffitt Cancer Center·2026
Octreotide as Adjunctive Therapy for Catecholamine-Secreting Pheochromocytoma and Paraganglioma.
The Journal of clinical endocrinology and metabolism·2026
Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Journal of comparative effectiveness research·2026